Plant Compounds for the Treatment of Diabetes, a Metabolic Disorder: NF-κB as a Therapeutic Target
- 10 November 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (39) , 4955-4969
Abstract
Background: The prevalence of diabetes in the world population hás reached 8.8 % and is expected to rise to 10.4% by 2040. Hence, there is an urgent need for the discovery of drugs against therapeutic targets to sojourn its prevalence. Previous studies proved that NF-κB serves as a central agent in the development of diabetic complications. Objectives: This review intended to list the natural plant compounds that would act as inhibitors of NF-κB signalling in different organs under the diabetic condition with their possible mechanism of action. Methods: Information on NF-κB, diabetes, natural products, and relation in between them, was gathered from scientific literature databases such as Pubmed, Medline, Google scholar, Science Direct, Springer, Wiley online library. Results and Conclusion: NF-κB plays a crucial role in the development of diabetic complications because of its link in the expression of genes that are responsible for organs damage such as kidney, brain, eye, liver, heart, muscle, endothelium, adipose tissue and pancreas by inflammation, apoptosis and oxidative stress. Activation of PPAR-α, SIRT3/1, and FXR through many cascades by plant compounds such as terpenoids, iridoids, flavonoids, alkaloids, phenols, tannins, carbohydrates, and phytocannabinoids recovers diabetic complications. These compounds also exhibit the prevention of NF-κB translocation into the nucleus by inhibiting NF-κB activators, such as VEGFR, RAGE and TLR4 receptors, which in turn, prevent the activation of many genes involved in tissue damage. Current knowledge on the treatment of diabetes by targeting NF-κB is limited, so future studies would enlighten accordingly.Keywords
Funding Information
- BSR-Faculty Fellowship (F.18-1/2011 (BSR))
- University Grants Commission (F117.1/2012-13/RGNF-2012-13-SC-AND 34335, F1-17.1/2015-16/RGNF-2015-17-SC-AND-17449)
This publication has 122 references indexed in Scilit:
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part IEuropean Heart Journal, 2013
- Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-κB pathways in diabetic neuropathyRedox Biology, 2013
- Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1Proceedings of the National Academy of Sciences, 2012
- SIRT1 is associated with a decrease in acute insulin secretion and a sex specific increase in risk for type 2 diabetes in Pima IndiansMolecular Genetics and Metabolism, 2011
- NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2011
- Epigenetic mechanisms in diabetic vascular complicationsCardiovascular Research, 2011
- Sirtuin-1 regulation of mammalian metabolismTrends in Molecular Medicine, 2011
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory responseHepatology, 2008
- Tumour vascularization: sprouting angiogenesis and beyondCancer and Metastasis Reviews, 2007
- Monocyte and macrophage heterogeneityNature Reviews Immunology, 2005